Analyst Notes: It's a tale of two regions when it comes to prescription barriers in the cancer pain market

Two reports out from FirstView examine the way market barriers such as, cost, market access, patient preferences, guidelines and recommendations, and more, affect the way medical oncologists in the US and the EU5 countries (France, Germany, Italy, Spain and the UK) prescribe treatments for cancer pain.

Though unrelated to safety or efficacy, market barriers nonetheless influence over 20% of prescriptions in the US, but only 12% in the EU5 countries. Most brands gain and lose market share as a result, but the reports show that only a few are net winners.

Based on surveys with medical oncologists, FirstView's Market Access Impact: Cancer Pain 2017 reports for the US and EU5 cover 6 cancer pain brands in the US (Actiq, Exalgo, Opana/Opana ER, Oxycontin and Subsys) and 7 brands in the EU5 (Abstral, Actiq, Effentora, Instanyl, Oxycontin, OxyNorm and PecFent).

The reports show how 7 different market barriers affect each brand's market share, and reveal which competitors each brand loses share to, and takes it from. Companies can download the reports directly from FirstView, saving them the time and expense of commissioning bespoke research.

In the US, most brands lose out to market barriers, with 5 of the 6 surveyed brands seeing a net loss. But while the winning brand dominates the US landscape currently, its market share would fall significantly in a barrier-free world. In terms of which barriers are having the most impact, no single barrier is to blame; 17% to 25% of surveyed doctors experience 3 or more barriers with the surveyed brands, but this rises to 4 barriers with some brands.

Moreover, some brands have a perception problem; up to 20% of doctors either wouldn't consider prescribing 5 of the surveyed brands, or haven't heard of them at all. When all is said and done, cost is a huge problem for 5 of the 6 brands included in the survey. Between 25% to 40% of doctors experience cost barriers with these 5 brands. That's at least 15% more than the leading competitor.

In contrast to the US, in the EU5, most brands gain market share due to barriers; 5 of the 7 surveyed brands see a net gain, albeit very small for some brands. Moreover, the overall barrier impact is small. Over 45& to 65% of surveyed doctors experience only 1 barrier with any given brand, but for some brands that climbs to 3 barriers.

Full reports available from FirstView

These and many other insights, along with the full survey results are available from the FirstView web site.

Interested parties can purchase and download FirstView Market Access Impact: Cancer Pain 2017 for the US and EU5 markets directly from the FirstView reports store.

Or contact FirstView for more information by calling +1 212-220-0880 or +44(0)20.7665.9240

To read more Analyst Notes articles, click here.